In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
UroGen Pharma Ltd (NASDAQ: URGN) closed the day trading at $19.85 up 0.35% from the previous closing price of $19.78. In other words, the price has increased by $0.35 from its previous closing price. On the day, 0.69 million shares were traded. URGN stock price reached its highest trading level at $20.1984 during the session, while it also had its lowest trading level at $19.17.
Ratios:
For a better understanding of URGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.99 and its Current Ratio is at 4.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $36.
On June 16, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 08 ’25 when Degnan Chris sold 2,203 shares for $16.85 per share. The transaction valued at 37,121 led to the insider holds 2,280 shares of the business.
Schoenberg Mark sold 871 shares of URGN for $16,645 on Sep 08 ’25. The Chief Medical Officer now owns 149,025 shares after completing the transaction at $19.11 per share. On Sep 08 ’25, another insider, Smith Jason Drew, who serves as the General Counsel of the company, sold 1,520 shares for $19.11 each. As a result, the insider received 29,047 and left with 43,305 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 918343040 and an Enterprise Value of 888858048. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.74. Its current Enterprise Value per Revenue stands at 9.432 whereas that against EBITDA is -7.275.
Stock Price History:
The Beta on a monthly basis for URGN is 1.06, which has changed by 0.6270492 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, URGN has reached a high of $21.71, while it has fallen to a 52-week low of $3.42. The 50-Day Moving Average of the stock is 7.55%, while the 200-Day Moving Average is calculated to be 47.56%.
Shares Statistics:
Over the past 3-months, URGN traded about 1.11M shares per day on average, while over the past 10 days, URGN traded about 842790 shares per day. A total of 46.20M shares are outstanding, with a floating share count of 42.41M. Insiders hold about 8.33% of the company’s shares, while institutions hold 92.50% stake in the company. Shares short for URGN as of 1760486400 were 11148494 with a Short Ratio of 10.03, compared to 1757894400 on 7943465. Therefore, it implies a Short% of Shares Outstanding of 11148494 and a Short% of Float of 24.47.
Earnings Estimates
The dynamic stock of UroGen Pharma Ltd (URGN) is currently being evaluated by a team of 7.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.16 and low estimates of -$0.67.
Analysts are recommending an EPS of between -$2.44 and -$3.45 for the fiscal current year, implying an average EPS of -$3.13. EPS for the following year is -$1.48, with 5.0 analysts recommending between -$0.6 and -$2.6.
Revenue Estimates
8 analysts predict $32.47M in revenue for. The current quarter. It ranges from a high estimate of $37.96M to a low estimate of $25.2M. As of. The current estimate, UroGen Pharma Ltd’s year-ago sales were $25.2MFor the next quarter, 8 analysts are estimating revenue of $42.75M. There is a high estimate of $53.34M for the next quarter, whereas the lowest estimate is $32.92M.
A total of 8 analysts have provided revenue estimates for URGN’s current fiscal year. The highest revenue estimate was $135.77M, while the lowest revenue estimate was $103.4M, resulting in an average revenue estimate of $119.7M. In the same quarter a year ago, actual revenue was $90.4MBased on 8 analysts’ estimates, the company’s revenue will be $260.82M in the next fiscal year. The high estimate is $391.48M and the low estimate is $224.86M.
